114 related articles for article (PubMed ID: 7188585)
21. An assessment of beta-adrenoceptor blockade in man by prizidilol hydrochloride.
Pitcher DW; Curry PV; Trounce JR
Br J Clin Pharmacol; 1982 May; 13(5):711-6. PubMed ID: 6123343
[TBL] [Abstract][Full Text] [Related]
22. Pulmonary effects in man of oral prizidilol hydrochloride (SK&F 92657), a new antihypertensive agent.
Edmondstone WM; Waller JF; Manghani KK; Hill PL; Bell AJ; Denison DM
Br J Clin Pharmacol; 1983 Dec; 16(6):591-8. PubMed ID: 6140939
[TBL] [Abstract][Full Text] [Related]
23. An analysis of blood pressure effects of nipradilol and prizidilol in normotensive and spontaneously hypertensive rats.
Watanabe TX; Sokabe H; Kawashima K
Jpn J Pharmacol; 1985 Jul; 38(3):273-9. PubMed ID: 3903298
[TBL] [Abstract][Full Text] [Related]
24. Cardiovascular effects in man of intravenous prizidilol hydrochloride (SK&F 92657); a new antihypertensive agent.
Edmonstone WM; Manghani KK; Bell AJ; McLeod M; Milton-Thompson GJ; Burland WL
Br J Clin Pharmacol; 1981 Oct; 12(4):567-72. PubMed ID: 7295490
[TBL] [Abstract][Full Text] [Related]
25. Clinical evaluation of the vasodilator MDL-899 in patients with essential hypertension.
Elliott HL; Campbell L; Sumner DJ; Reid JL
J Cardiovasc Pharmacol; 1985; 7(5):948-52. PubMed ID: 2413306
[TBL] [Abstract][Full Text] [Related]
26. Dose-response curve and time course of the antihypertensive effect of SKF 92 657, a beta-receptor-blocking and vasodilating compound.
Leonetti G; Terzoli L; Sala C; Bianchini C; Zanchetti A
Clin Sci (Lond); 1980 Dec; 59 Suppl 6():461s-463s. PubMed ID: 6108817
[TBL] [Abstract][Full Text] [Related]
27. Manidipine: a review of its use in hypertension.
Cheer SM; McClellan K
Drugs; 2001; 61(12):1777-99. PubMed ID: 11693466
[TBL] [Abstract][Full Text] [Related]
28. Effects of celiprolol on plasma renin, aldosterone, norepinephrine and epinephrine in primary hypertension.
Kimura S; DeQuattro V; Hernandez PH; Lee DD
Am J Cardiol; 1988 Oct; 62(10 Pt 1):751-4. PubMed ID: 2971310
[TBL] [Abstract][Full Text] [Related]
29. Felodipine, a new vasodilating drug: blood pressure, cardiac, renal, and humoral effects in hypertensive patients.
Leonetti G; Gradnik R; Terzoli L; Fruscio M; Rupoli L; Zanchetti A
J Cardiovasc Pharmacol; 1984; 6(3):392-8. PubMed ID: 6202963
[TBL] [Abstract][Full Text] [Related]
30. The pharmacodynamics and dose-response relationships of the angiotensin converting enzyme inhibitor, cilazapril, in essential hypertension.
Ajayi AA; Elliott HL; Reid JL
Br J Clin Pharmacol; 1986 Aug; 22(2):167-75. PubMed ID: 3019375
[TBL] [Abstract][Full Text] [Related]
31. Pharmacological properties of the stereoisomers of prizidilol: their use in analysis of reflex tachycardia and blood pressure control in normotensive cats, rats, and dogs.
Owen DA; Eden RJ; Lamb MS; Taylor EM
J Cardiovasc Pharmacol; 1986; 8(4):743-8. PubMed ID: 2427813
[TBL] [Abstract][Full Text] [Related]
32. Antihypertensive activity of a new vasodilator, cadralazine, administered alone or in combination with a beta-blocker.
Buoninconti R; Motolese M
Int J Clin Pharmacol Ther Toxicol; 1985 Nov; 23(11):613-6. PubMed ID: 2867048
[TBL] [Abstract][Full Text] [Related]
33. Dose response and safety of telmisartan in patients with mild to moderate hypertension.
Smith DH; Matzek KM; Kempthorne-Rawson J
J Clin Pharmacol; 2000 Dec; 40(12 Pt 1):1380-90. PubMed ID: 11185637
[TBL] [Abstract][Full Text] [Related]
34. The effect of 8 weeks treatment with the calcium antagonist felodipine on blood pressure, heart rate, working capacity, plasma renin activity, plasma angiotensin II, urinary catecholamines and aldosterone in patients with essential hypertension.
Katzman PL; Hulthén UL; Hökfelt B
Br J Clin Pharmacol; 1986 Jun; 21(6):633-40. PubMed ID: 3527242
[TBL] [Abstract][Full Text] [Related]
35. The 24 h blood pressure responses of hypertensives to a once-a-day cilazapril regimen.
Fernandez PG; Bolli P; Lee C
Can J Cardiol; 1990 Mar; 6(2):53-8. PubMed ID: 2138051
[TBL] [Abstract][Full Text] [Related]
36. Cadralazine, a new vasodilator, in addition to a beta-blocker for long-term treatment of hypertension.
Salvadeo A; Villa G; Segagni S; Piazza V; Picardi L; Romano M; Parini J
Arzneimittelforschung; 1985; 35(3):623-5. PubMed ID: 2859865
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and tolerability of once-daily oral fimasartan 20 to 240 mg/d in Korean Patients with hypertension: findings from Two Phase II, randomized, double-blind, placebo-controlled studies.
Lee H; Yang HM; Lee HY; Kim JJ; Choi DJ; Seung KB; Jeon ES; Ha JW; Rim SJ; Park JB; Shin JH; Oh BH
Clin Ther; 2012 Jun; 34(6):1273-89. PubMed ID: 22608107
[TBL] [Abstract][Full Text] [Related]
38. Measurement of plasma renin concentration instead of plasma renin activity decreases the positive aldosterone-to-renin ratio tests in treated patients with essential hypertension.
Lonati C; Bassani N; Gritti A; Biganzoli E; Morganti A
J Hypertens; 2014 Mar; 32(3):627-34. PubMed ID: 24445391
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the effects of prizidilol and propranolol on renal haemodynamics at rest and during exercise.
Malini PL; Strocchi E; Ambrosioni E
Br J Clin Pharmacol; 1984 Mar; 17(3):251-5. PubMed ID: 6712858
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and tolerability of nisoldipine coat-core formulation in the treatment of essential hypertension: The South African Multicenter ANCHOR Study. Ambulatory Nisoldipine Coat-Core Hypertension Outpatient Response (ANCHOR) Investigators.
Opie LH; Müller FO; Myburgh DP; Rosendorff C; Sareli P; Seedat YK; Weich DJ; Luus HG
Am J Hypertens; 1997 Mar; 10(3):250-60. PubMed ID: 9056681
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
